A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal
- Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal.
- The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal.
- Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A deals in Europe.
- He’s leveraged that experience to land advisory roles with multinational companies since starting his own firm.
Novartis on Monday announced its $8.7 billion acquisition of gene-therapy firm AveXis, which could add billions in new revenue for the Swiss drugmaker.
The deal is expected to close in the middle of this